Related Experiment Video

Updated: Jul 13, 2026

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

[Pathomechanism of metabolic disorders in HCV infection]

Anna Boroń-Kaczmarska1

  • 1Katedra i Klinika Chorób Zakaznych i Hepatologii Pomorskiej Akademii Medycznej w Szczecinie.

Przeglad Epidemiologiczny
|August 9, 2007
PubMed

Insights

Hepatitis C virus (HCV) infection is linked to fatty liver and insulin resistance. The exact mechanisms are unclear, but steatosis is metabolic in genotype 1 and virus-induced in genotype 3 infections.

Area of Science:

  • Hepatology
  • Virology
  • Endocrinology

Context:

  • Hepatitis C virus (HCV) infection is increasingly associated with metabolic complications.
  • Fatty liver disease (steatosis) and insulin resistance are frequently observed in HCV patients.
  • The interplay between HCV, steatosis, and metabolic syndrome requires further elucidation.

Purpose:

  • To explore the relationship between hepatitis C virus infection, hepatic steatosis, and insulin resistance.
  • To investigate the underlying pathomechanisms contributing to fatty liver in HCV patients.
  • To differentiate the causes of steatosis based on HCV genotype.

Summary:

  • Recent reports highlight a strong correlation between HCV, steatosis, and insulin resistance.
  • Fatty liver in HCV patients often presents with metabolic syndrome features.
  • Pathomechanisms remain largely unclear, with distinct etiologies for different HCV genotypes.
  • Steatosis is primarily metabolic in HCV genotype 1 infections.
  • Steatosis is predominantly virus-induced in HCV genotype 3 infections.

Impact:

  • This research contributes to understanding the complex pathophysiology of HCV-associated metabolic dysfunction.
  • Clarifying the mechanisms can inform targeted therapeutic strategies for HCV patients.
  • Differentiating genotype-specific steatosis may lead to personalized treatment approaches.
  • Improved management of metabolic complications in HCV could enhance patient outcomes.

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...